Tumor Necrosis Factor Alpha News and Research

RSS

Extract of medicinal plant Artemisia annua interferes with replication of SARS-CoV-2 in vitro

Researchers in the United States have shown that extracts of an aromatic herb called Artemisia annua inhibit the replication of severe acute respiratory coronavirus (SARS-CoV-2) – the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

11 Jan 2021

Antibodies and inflammatory markers are pervasive in colostrum of SARS-CoV-2 infected women

A recent study, currently available on the medRxiv* preprint server, is among the first to reveal the presence of antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in colostrum and to demonstrate elevated cytokine levels in colostrum from women exposed to the virus.

7 Jan 2021

Recovered COVID-19 patients exhibit persistent cellular immunity

Researchers at The Rockefeller University in New York have conducted a study showing that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – triggers persistent T cell responses that last for at least six months.

14 Dec 2020

Head injuries and long sleep deprivation can affect neurogenerative processes

Scientists from the School of Biomedicine of Far Eastern Federal University (FEFU) with colleagues from Italy, Spain, Romania, and Sweden suggest a way to protect the brain and minimize neurodegenerative processes after concussion head injuries in the presence of extensive previous sleep deprivation.

9 Dec 2020

FASLG gene may drive cytokine-linked adverse COVID-19 outcomes with age

A new study published on the preprint server bioRxiv in December 2020 reveals the role played by certain genetic factors in this group, in particular the FASLG gene belonging to the tumor necrosis factor (TNF) family.

8 Dec 2020

Uracil point mutations found in SARS-CoV-2 variants alter innate immune responses

Tohoku University scientists have found that human editing enzymes are likely behind a type of mutation in the COVID-19 virus that stimulates the release of pro-inflammatory molecules called cytokines by immune cells in the body.

11 Nov 2020

Engineered, high-affinity ACE2 receptors neutralize SARS-CoV-2

In a study published in the preprint server bioRxiv, researchers from the Kyoto Prefectural University of Medicine and Osaka University Japan, discuss how they engineered ACE2 to enhance its affinity to RBD in human cells.

17 Sep 2020

Keto diet could be beneficial for elderly COVID-19 patients

A recent study by researchers at Yale School of Medicine, New York University Langone Health and Washington University School of Medicine, claims that the ketogenic diet (high fat, low carbohydrate diet) is capable of mitigating clinical outcomes of coronavirus disease 2019 (COVID-19) in elderly people by improving immune-metabolic functions and reducing inflammation. The study is currently available on the bioRxiv* preprint server.

14 Sep 2020

COVID-19 is not characterized by a cytokine storm, shows study

Does the COVID-19 cytokine storm exist? Inflammatory proteins, also known as cytokines, play a crucial role in the immune response. If this immune response is too strong, a phenomenon known as "cytokine storm", it can cause harm to the patient.

5 Sep 2020

New bivalent vaccine delivers robust cell-mediated and humoral immunity against SARS-CoV-2

In a groundbreaking bioRxiv study, US researchers demonstrate the capability of next-generation bivalent human adenovirus serotype 5 (hAd5) vaccine for inducing both cellular and humoral immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – using both an S protein sequence optimized for cell surface expression and a conserved nucleocapsid antigen designed to be transported to the endosomal subcellular compartment.

2 Aug 2020

Study reveals manifold applications of cytokine transcriptional response modules in COVID-19

In a recent bioRxiv* study, UK researchers used interleukin modules to investigate the pathology of coronavirus disease (COVID-19).

27 Jul 2020

BMI should be assessed in management of COVID-19 patients

A new study published on the preprint server medRxiv* in June 2020 reports that obesity is a risk factor of composite poor outcome of COVID-19 disease. On the other hand, COVID-19 patients with 'composite poor outcome' have higher BMI. Therefore, BMI should be assessed in the management of COVID-19 patients, and special attention should be given to patients with obesity.

1 Jul 2020

Progression and severity of COVID-19 highly dependant on cytokine changes

A new review paper by the researchers from Spain, published in the journal Cytokine & Growth Factor Reviews, demonstrates how changes in the levels of cytokines and other biomolecules are associated with the presence and more serious prognosis of coronavirus disease (COVID-19).

11 Jun 2020

Kidney enzyme renalase a potential therapy for severe COVID-19

Researchers from Yale School of Medicine have discovered that a low blood level of an enzyme called renalase is associated with severe coronavirus disease 2019 (COVID-19).

7 Jun 2020

Nanostimulators can amp up stem cells' regenerative powers for muscle repair

In regenerative medicine, an ideal treatment for patients whose muscles are damaged from lack of oxygen would be to invigorate them with an injection of their own stem cells.

3 May 2020

Mapping complex peripheral immune response to severe COVID-19

In a recent article publicly available at medRxiv, researchers from Stanford have presented a single-cell atlas of the peripheral immune response to coronavirus disease (COVID-19), highlighting pertinent immunological features associated with the severe forms of the disease.

26 Apr 2020

Study advances the understanding of capillary regression

Many diseases arise from abnormalities in our capillaries, tiny exquisitely branching blood vessel networks that play a critical role in tissue health.

29 Jan 2020

Study: MIB2 improves inflammation by degrading CYLD enzyme

The tumor suppressor CYLD lysine 63 deubiquitinase (CYLD) is a deubiquitinating enzyme that suppresses polyubiquitin-dependent signaling pathways, including the proinflammatory and cell growth-promoting NF-κB pathway.

30 Oct 2019

Discovery sheds light on TNFα protein's role in impairing memory in Alzheimer's disease

Otago scientists have made an important discovery in understanding the role a particular protein plays to impair memory in Alzheimer's disease, which could lead to more effective treatment in future.

23 Oct 2019

Acne may be a natural, transient inflammatory state when facial skin is exposed to microbes

Adolescent acne does not always result in a pathological condition; rather, it may be a natural, transient inflammatory state occurring when the maturing facial skin is exposed to new microbes and enhanced production of an oily substance called sebum, according to a Forum article published on September 26 in the journal Trends in Immunology.

25 Sep 2019